The fertility company Spermosens reports no revenue in the second quarter, as planned. The loss increased.Operating profit, as well as both profit before and after tax, amounted to -2.8 million Swedish kronor (-2.7). Earnings per share amounted to -0.001 Swedish kronor (-0.020). Cash flow from operating activities amounted to -2.5 million Swedish kronor (-1.6). Cash and cash equivalents amounted to 1.9 million Swedish kronor (11.8).Spermosens has had stronger-than-expected patient recruitment for the clinical validation of the third-generation JUNO-Checked and continues to plan to complete the study before year-end. CEO Tore Duvold writes this in the interim report.A total of 44 patients had been recruited at the Reproductive Medicine Centre in Malmö before the summer break. In parallel, the company has broadened discussions with potential commercial, clinical and manufacturing partners, with the ambition of eventually entering into licensing agreements.During the quarter, Spermosens also secured a capital facility of 4.85 million Swedish kronor before issue costs. According to the company, it finances operations for the remainder of the year, while warrants in November may provide additional capital.Spermosens, SEK millionQ2-2026Q2-2025ChangeNet sales00Operating profit-2.8-2.7Profit before tax-2.8-2.7Net profit-2.8-2.7Earnings per share, Swedish kronor-0.001-0.020Cash flow from operating activities-2.5-1.6Cash and cash equivalents1.911.8-83.9%